https://mindmedicinelaw.com/briefing/5-meo-dmt-from-toad-venom-clinical-trial-for-depression-in-2026-20261026-54065The Psychedelic Journalen2026-10-26T22:06:21.323921+00:005-MeO-DMT From Toad Venom: Clinical Trial for Depression in 20265-meo-dmt, toad venom, treatment-resistant depression, psychedelic clinical trials, fda guidance, psychiatric research, synthetic vs natural psychedelics, schedule i substances, ecological impact, psychedelic regulationhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-therapy-program-first-real-world-study-findings-20261026-54066The Psychedelic Journalen2026-10-26T22:06:01.559772+00:00Oregon’s Psilocybin Therapy Program: First Real-World Study Findingspsilocybin therapy, oregon health authority, psychedelic regulation, real-world evidence, mental health policy, facilitator training, adverse events, access disparities, clinical outcomes, state-level legalizationhttps://mindmedicinelaw.com/briefing/fda-leadership-issues-formal-policy-statement-on-psychedelics-20261026-54064The Psychedelic Journalen2026-10-26T22:05:42.070780+00:00FDA Leadership Issues Formal Policy Statement on Psychedelicsfda psychedelics policy, psychedelic drug approval, clinical trial design, therapist training requirements, regulatory risk, real-world evidence, psychedelic industry, post-marketing surveillance, mental health therapieshttps://mindmedicinelaw.com/briefing/self-compassion-in-mdma-assisted-therapy-for-social-anxiety-early-clinical-insig-20261025-53969The Psychedelic Journalen2026-10-26T22:06:38.826737+00:00Self-Compassion in MDMA-Assisted Therapy for Social Anxiety: Early Clinical Insightsmdma-assisted therapy, self-compassion, social anxiety disorder, psychedelic clinical trials, mechanisms of action, internalized shame, depressive symptoms, treatment moderators, trial design, psychological mechanismshttps://mindmedicinelaw.com/briefing/israel-s-national-mdma-and-psilocybin-ptsd-trial-scope-and-implications-20261025-53890The Psychedelic Journalen2026-10-25T22:04:47.335672+00:00Israel’s National MDMA and Psilocybin PTSD Trial: Scope and Implicationsisrael, mdma, psilocybin, ptsd, clinical trial, psychedelic research, government policy, international, mental health, regulatoryhttps://mindmedicinelaw.com/briefing/israel-s-health-ministry-launches-national-psychedelic-ptsd-trial-20261025-53723The Psychedelic Journalen2026-10-25T15:05:13.883479+00:00Israel’s Health Ministry Launches National Psychedelic PTSD Trialisrael health ministry, psychedelic clinical trial, ptsd treatment, government policy, public health integration, clinical research, mdma, psilocybin, mental health innovationhttps://mindmedicinelaw.com/briefing/esketamine-use-and-postoperative-mental-health-in-elderly-chinese-patients-20261024-53997The Psychedelic Journalen2026-10-26T22:07:33.030878+00:00Esketamine Use and Postoperative Mental Health in Elderly Chinese Patientsesketamine, postoperative anxiety, postoperative depression, elderly patients, china, perioperative mental health, nmda antagonist, clinical trials, psychedelic research, public healthhttps://mindmedicinelaw.com/briefing/muscarinic-signaling-and-prefrontal-stm-implications-for-neuropsychiatric-drug-d-20261024-53996The Psychedelic Journalen2026-10-26T22:07:12.648937+00:00Muscarinic Signaling and Prefrontal STM: Implications for Neuropsychiatric Drug Developmentmuscarinic signaling, prefrontal cortex, short-term memory, thalamic drive, acetylcholine, neuropsychiatric therapeutics, cognitive enhancement, mechanistic neuroscience, psychedelic drug development, clinical trial designhttps://mindmedicinelaw.com/briefing/validated-recovery-curves-for-phq-8-and-gad-7-in-outpatient-care-20261024-53998The Psychedelic Journalen2026-10-26T22:06:56.508249+00:00Validated Recovery Curves for PHQ-8 and GAD-7 in Outpatient Caremeasurement-based care, phq-8, gad-7, recovery curves, psychedelic clinical trials, outpatient mental health, treatment failure prediction, depression endpoints, anxiety endpointshttps://mindmedicinelaw.com/briefing/mri-biomarkers-in-schizophrenia-and-trd-limited-clinical-utility-20261022-53664The Psychedelic Journalen2026-10-25T15:06:32.885155+00:00MRI Biomarkers in Schizophrenia and TRD: Limited Clinical Utilitymri biomarkers, schizophrenia, treatment-resistant depression, hippocampal alterations, prefrontal cortex, psychedelic trials, neuroimaging endpoints, biomarker validation, clinical translationhttps://mindmedicinelaw.com/briefing/genetic-biomarkers-and-antidepressant-response-implications-for-psychedelic-psyc-20261021-53669The Psychedelic Journalen2026-10-25T15:06:47.779350+00:00Genetic Biomarkers and Antidepressant Response: Implications for Psychedelic Psychiatrypolygenic scores, major depressive disorder, ssri response, genetic biomarkers, precision psychiatry, psychedelic research, gabaergic pathway, personalized medicine, pharmacogenomics, clinical trialshttps://mindmedicinelaw.com/briefing/dextromethorphan-bupropion-vs-esketamine-us-mdd-cost-outcomes-20261021-53670The Psychedelic Journalen2026-10-25T15:05:30.861894+00:00Dextromethorphan-Bupropion vs Esketamine: US MDD Cost Outcomesdextromethorphan-bupropion, auvelity, esketamine, major depressive disorder, healthcare costs, claims data, comparative effectiveness, payer policy, real-world evidence, psychedelic researchhttps://mindmedicinelaw.com/briefing/media-vs-clinical-evidence-psilocybin-efficacy-and-risk-reporting-20261020-53648The Psychedelic Journalen2026-10-25T15:05:44.055975+00:00Media vs. Clinical Evidence: Psilocybin Efficacy and Risk Reportingpsilocybin clinical trials, media reporting, psychedelic therapy risks, evidence communication, public health policy, systematic review, mental health indications, safety reporting, research ethicshttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-habenula-activity-implications-for-depression-policy-20261019-53684The Psychedelic Journalen2026-10-25T15:05:58.046163+00:00Ketamine’s Impact on Habenula Activity: Implications for Depression Policyketamine, habenula, depression, mechanism of action, psychiatric policy, clinical trials, FDA, biomarkers, neuroimaging, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/ketamine-integration-in-emergency-care-evidence-from-2026-review-20261018-53881The Psychedelic Journalen2026-10-25T22:04:59.512028+00:00Ketamine Integration in Emergency Care: Evidence from 2026 Reviewketamine, emergency care, clinical protocols, acute pain management, sedation, policy implications, hospital guidelines, safety considerations, opioid alternativeshttps://mindmedicinelaw.com/briefing/psilocybin-neuroplasticity-without-hallucinations-5-ht2a-layer-5-insights-20261015-53626The Psychedelic Journalen2026-10-25T15:06:17.127815+00:00Psilocybin: Neuroplasticity Without Hallucinations—5-HT2A Layer 5 Insightspsilocybin, 5-HT2A receptor, layer 5 pyramidal neurons, neuroplasticity, hallucinogenic effects, psychedelic drug development, clinical trial design, biomarkers, regulatory strategy